Published: 2022-03-04

Editorials

Using Genomics to Improve Pigmented Lesion Management & Health Outcomes

Clay Cockerell, Roger Ceilley, Mark Lebwohl, Darrell Rigel
| DOI https://doi.org/10.25251/skin.6.2.1

Page 87-89

In-Depth Reviews

Original Research

Research Letters

Weekly Isotretinoin Therapy (WIT) Study: A Potential Alternative for the Treatment of Moderate Acne Vulgaris

Samantha Karlin, Alexandra Ritter, Courtney Linkous, Katherine Wehlage, Lara Wine Lee
| DOI https://doi.org/10.25251/skin.6.2.6

Page 132-134

PDF KOL SUMMARY

Brief Articles

Successful Dupilumab Treatment of Atopic Dermatitis in a Liver Transplant Patient

Amanda Krenitsky, Sairekha Ravichandran, Joel Cohen, Jonathan Braue, Lilia Correa-Selm
| DOI https://doi.org/10.25251/skin.6.2.7

Page 135-137

Wells Syndrome with Sustained Response to Omalizumab

Kezia Surjanto, Gage Rensch, Garrett Vick, Andrea Murina
| DOI https://doi.org/10.25251/skin.6.2.8

Page 138-142

Case Report and Review of Eccrine Porocarcinoma in Skin of Color

Sadhana Sruveera Sathi, Elizabeth M. Dugan, Maral Skelsey
| DOI https://doi.org/10.25251/skin.6.2.9

Page 143-148

SARS-Cov-2 Infection Uncovering Latent Mycobacterium Leprae Infection

Christopher Mancuso, DO, MHS, Paloma Reiter, DO, Regina Zambrano, DO, Ritu Saini, MD, Suzanne Sirota-Rozenberg, DO
| DOI https://doi.org/10.25251/skin.6.2.12

Page 157-161

A Diagnostic Challenge: Desmoplastic Melanoma

Katie O'Connell, Ryan Svoboda, Bryan Anderson, Klaus Helm, Kimberly Ken
| DOI https://doi.org/10.25251/skin.6.2.13

Page 162-165

COVID Concepts

Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35)

Sophie Guenin, Emily Elbogen , Mindy Kresch , Mark Lebwohl
| DOI https://doi.org/10.25251/skin.6.2.14

Page 166-169

Short Communications

Surprise Medical Billing Reform: Considerations for Dermatology

Yuangao Liu, Natalie Skopicki, Harrison Nguyen, Travis Blalock
| DOI https://doi.org/10.25251/skin.6.2.18

Page 177-179

Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis

Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials

Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley
| DOI https://doi.org/10.25251/skin.6.supp.1

Page s1

Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2

Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley
| DOI https://doi.org/10.25251/skin.6.supp.2

Page s2

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt
| DOI https://doi.org/10.25251/skin.6.supp.4

Page s4

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Leon Kircik, Philip Brown, Anna Tallman, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.6.supp.5

Page s5

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik
| DOI https://doi.org/10.25251/skin.6.supp.6

Page s6

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal Desai, Brad Glick, Howard Sofen, Anna Tallman, David Rubenstein, Janine Fournier, Philip Brown
| DOI https://doi.org/10.25251/skin.6.supp.7

Page s7

Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial

Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman
| DOI https://doi.org/10.25251/skin.6.supp.8

Page s8

Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies

Kristian Reich , April Armstrong , Yaowei Zhu, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Peter Foley, Christopher Griffiths, Bruce Strober
| DOI https://doi.org/10.25251/skin.6.supp.11

Page s11

SKINmages: Clinical Images in Dermatology

Auricular Distortion Following Cryotherapy

Jason Bard, Heather Kornmehl , Joesph Wentzell
| DOI https://doi.org/10.25251/skin.6.2.19

Page 180-182

An Uncommon Presentation Of Erosive Pustular Dermatosis: A Large, Crusted Plaque On The Scalp

James MacKenzie, Miriam Sagher, Ethan Sagher, Ben Friedman, Jesse Veenstra
| DOI https://doi.org/10.25251/skin.6.2.20

Page 183-185

Acne & Rosacea

Treating Acne in Obese and Morbidly Obese Patients With Tazarotene 0.045% Lotion: Post Hoc Analysis of Pooled Phase 3 Data

Jonette Keri, Leon Kircik, Lawrence Green, Glynis Ablon, William Werschler, Emil Tanghetti, Zoe Draelos, Eric Guenin
| DOI https://doi.org/10.25251/skin.6.supp.12

Page s12

A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin  

James Del Rosso, Jeffrey Sugarman , Michael Gold, Krysten Arekapdui, Lawrence Green
| DOI https://doi.org/10.25251/skin.6.supp.16

Page s16

Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug

James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti
| DOI https://doi.org/10.25251/skin.6.supp.17

Page s17

Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Different Adult Age Groups

Neil Sadick, Fran Cook-Bolden, Kenneth Beer, Zoe Draelos, Leon Kircik, Emil Tanghetti, Eric Guenin
| DOI https://doi.org/10.25251/skin.6.supp.18

Page s18

Skin Cancer

Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol

Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee
| DOI https://doi.org/10.25251/skin.6.supp.19

Page s19

Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma

Angela Moore, Stephen Moore, Qin He, Peter Rady, Ayman Grada, Stephen Tyring
| DOI https://doi.org/10.25251/skin.6.supp.20

Page s20

Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions

Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.6.supp.25

Page s25

Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl
| DOI https://doi.org/10.25251/skin.6.supp.26

Page s26

Atopic Dermatitis

Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Lawrence Eichenfeld, Eric Simpson, Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Seth Forman, Michael Kuligowski, May Venturanza, Haobo Ren, Amy Paller
| DOI https://doi.org/10.25251/skin.6.supp.28

Page s28

Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson
| DOI https://doi.org/10.25251/skin.6.supp.s29

Page s29

Miscellaneous

Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US

Shari Lipner, Warren Joseph , Tracey Vlahovic, Richard Scher, Phoebe Rich, Mahmoud Ghannoum, Ralph Daniel, Boni Elewski
| DOI https://doi.org/10.25251/skin.6.supp.s31

Page s31